QR Code (код быстрого отклика)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC

Introduction: MET amplification is an important genetic alteration in NSCLC. Unlike in patients with EGFR and ALK alterations, the efficacy of immune checkpoint inhibitors in patients with MET-amplified NSCLC remains unknown. Methods: An exploratory analysis of a prospective, multi-institutional coh...

Полное описание

Сохранить в:
Главные авторы: Katsuhiro Yoshimura, MD, PhD, Yusuke Inoue, MD, PhD, Naoki Inui, MD, PhD, Masato Karayama, MD, PhD, Hideki Yasui, MD, PhD, Hironao Hozumi, MD, PhD, Yuzo Suzuki, MD, PhD, Kazuki Furuhashi, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Noriyuki Enomoto, MD, PhD, Yutaro Nakamura, MD, PhD, Haruhiko Sugimura, MD, PhD, Takafumi Suda, MD, PhD
Формат: Artigo
Язык:Inglês
Опубликовано: Elsevier 2021-11-01
Серии:JTO Clinical and Research Reports
Предметы:
Lung cancer
MET
Nivolumab
Amplification
Immune checkpoint inhibitor
Online-ссылка:http://www.sciencedirect.com/science/article/pii/S2666364321000989
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы